Drug intelligence / Profile preview

bupivacaine + epinephrine + dexamethasone

Development stage: Unknown
Lead developer: Leiters Health
Modality: Small Molecules
Administration: Perineural, Local Infiltration

Overview

A combination of three non-opioid drugs used for local and regional anesthesia. Bupivacaine is a long-acting local anesthetic, epinephrine is a vasoconstrictor that prolongs the anesthetic effect, and dexamethasone is a corticosteroid that extends the duration of analgesia. This combination is primarily used for nerve blocks, particularly interscalene brachial plexus blocks, to provide prolonged post-operative pain relief.

Other names: bupivacaine/dexamethasone/epinephrinebupivacaine dexamethasone plus epinephrine

Targets

NaV (Voltage-gated sodium channels)AR (Adrenergic receptors)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on bupivacaine + epinephrine + dexamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bupivacaine + epinephrine + dexamethasone.

Explore the full profile